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manchester.ac.ukAbstract3-M syndrome is an autosomal recessive disorder characterised by pre- and post-natal growth
restriction, facial dysmorphism, normal intelligence and radiological features (slender long
bones and tall vertebral bodies). It is known to be caused by mutations in the genes encoding
cullin 7, obscurin-like 1 and coiled-coil domain containing 8. The mechanisms through which
mutations in these genes impair growth are unclear. The aim of this study was to identify novel
pathways involved in the growth impairment in 3-M syndrome. RNA was extracted from
fibroblast cell lines derived from four 3-M syndrome patients and three control subjects,
hybridised to Affymetrix HU 133 plus 2.0 arrays with quantitative real-time PCR used to
confirm changes found on microarray. IGF-II protein levels in conditioned cell culture media
were measured by ELISA. Of the top 10 downregulated probesets, three represented IGF2
while H19 was identified as the 23rd most upregulated probeset. QRT-PCR confirmed
upregulation of H19 (P!0.001) and downregulation of IGF2 (P!0.001). Levels of IGF-II
secreted into conditioned cell culture medium were higher for control fibroblasts than those
for 3-M fibroblasts (10.2G2.9 vs 0.6G0.9 ng/ml, P!0.01). 3-M syndrome is associated with a
gene expression profile of reduced IGF2 expression and increased H19 expression similar to
that found in Silver–Russell syndrome. Loss of autocrine IGF-II in the growth plate may be
associated with the short stature seen in children with 3-M syndrome.Key Words
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.0 UEndocrine Connections
(2013) 2, 225–235Introduction3-M syndrome (named after the first three authors to describe
thecondition) is anautosomal recessivedisordercharacterised
by impaired pre- and post-natal growth, facial dysmorphism
(triangular shaped face, anteverted nares, full fleshy lips),
prominent heels, normal intelligence and, in some, radio-
logical features (slender long bones and tall vertebral bodies).
It iscausedbylossoffunctionmutations inthegenesencodingcullin 7 (CUL7) (1), obscurin-like 1 (OBSL1) (2) and coiled-coil
domain containing 8 (CCDC8) (3). CUL7 is a scaffold protein
forming part of an E3 ubiquitin ligase enzyme responsible
for cytoplasmic protein degradation (4), while OBSL1 is a
cytoskeletal adaptor proteinwhich localises to theperinuclear
region (5). The function of CCDC8 is unknown, but it binds
to OBSL1 (3) and is required for p53-mediated apoptosis (6).sed under a Creative Commons
nported License.
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Research P G Murray et al. 3-M syndrome and IGF2 2–11 2 :226Themechanisms leadingto thegrowth impairmentseen
in 3-M syndrome remain unclear, but are likely to relate to
abnormalities inbasic cellular growthaswell as alterations in
cellular responses to growth factor stimulation. TheCul7K/K
mousedisplays impairedpre-natalgrowthandabnormalities
in placental vasculature, but dies from respiratory distress
after birth (7). Suggested targets for the CUL7 containing E3
ubiquitin ligase enzyme include cyclin D1 (8) and IRS1 (9).
Altered IGF-I signalling with increased activation of the
downstream signalling molecule AKT was identified in
Cul7K/Kmouse embryonic fibroblasts (MEFs) (9), associated
with poor cell growth and senescence. Overexpression of
CUL7 in an immortalised cancer cell line leads to decreased
p53-mediated apoptosis (10, 11, 12). In contrast to the
data in MEFs, AKT signalling was reduced in human skin
fibroblast cell lines derived from3-M syndromepatients (13)
(including one patient with a CUL7 nonsense mutation).
Alterations in the levels of the insulin-like growth factor-
binding proteins (IGFBPs) have been identified in 3-M
syndrome patient cell lines, both at the RNA level for
IGFBP2 and 5 (14) and at the protein level for IGFBP2, 5 and
7 (13). Alterations in IGFBP levels and IGF-I signal
transduction are seen in cell lines with OBSL1 and CCDC8
mutations (13) aswell asCUL7mutations; there is, however,
a paucity of other data on the link between OBSL1, CCDC8
and CUL7 and the mechanism of growth impairment.
Although3-M syndrome is considered to be a relatively
uncommon disorder, it is probably an under recognised
condition (6); its core characteristics of pre- and post-natal
growth impairment are sharedwith all small for gestational
age (SGA) children with failure of catch up growth. This
includes many children in whom there is as yet no clear
mechanism of growth impairment. The aim of this study
was to identify novel potential mechanisms of growth
impairment in3-Msyndrome, as anexemplar condition for
SGA, by examining the transcriptome of skin fibroblast cell
lines derived from 3-M patients. Skin fibroblast cell lines
have previously been useful in the study of other growth
disorders (15, 16). An understanding of the mechanisms
of growth impairment in 3-M syndrome could lead to
insights into the causation of poor growth in other SGA
children and potential targets for molecular diagnostics.Subjects and methods
Patients
Skin fibroblast cell lines were derived from four 3-M
syndrome patients and three control subjects. Biopsies were
obtained from the forearm after application of EMLA creamhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0065
 2013 The authors
Published by Bioscientifica Ltd(AstraZeneca). The patients included one male with a
homozygous CUL7mutation (c.4191delC p.H1379HfsX11),
one male with a homozygous OBSL1mutation (c.1273insA,
p.T425NfsX40, referred to asOBSL1Mhere), one femalewith
a homozygousOBSL1mutation (c.1273insA, p.T425NfsX40,
referred to as OBSL1F) and one female with a homozygous
CCDC8 mutation (c.84dup, p.L29X). The three control
fibroblast cell lines (two males and one female) were
derived from skin obtained during removal of skin tags. All
patients and control subjects were prepubertal at the time
the skin samples were obtained. All patients with 3-M
syndrome had clinical features of the condition including
growth impairment.Cell culture
Fibroblast cells were cultured in 75 cm2 cell culture flasks
(Corning, Tewkesbury, MA, USA) in DMEM (Invitrogen
Paisley, Renfrewshire, UK) supplemented to a final
concentration with 10% foetal bovine serum (Invitrogen),
50 units/ml penicillin, 50 mg/ml streptomycin, 2 mM
glutamine and 2.5 mg/ml amphoteracin B (Invitrogen).WST-8 cell growth assay
Cells were seeded at a density of 1000 cells/cm2 in 96-well
cell culture plates (Corning) in 100 ml cell culture media:
24 and 72 h after seeding, 10 ml WST-8 was added to each
well, the plate was incubated for 2 h at 37 8C before
measuring absorbance at 450 nm on a u.v. spectro-
photometer (Bio-Rad Benchmark microplate reader,
Bio-Rad UK). For each cell line at each time measurement,
a minimum of eight independent wells were examined
on three separate occasions.5-Ethynyl-2 0-deoxyuridine incorporation
Cells were seeded at a density of 1000 cells/cm2 into 8-well
chamberslides (Scientific Laboratory Supplies, Hessle,
Yorkshire, UK) and incubated for 24 h in 600 ml cell culture
media at 37 8C in 5% CO2. After 24 h, the culture medium
was removed and replaced with media containing 40 mM
5-ethynyl-2 0-deoxyuridine (EdU) for 3 h with the cells
incubated in standard conditions. The media was then
removed and the cells washed, fixed and permeabilised.
EdU incorporation was assessed using the Click-iT EdU
Alexa Fluor 488 Imaging Kit *for 50 coverslips (Invitrogen)
as per the manufacturer’s instructions. DAPI was used to
identify the total number of cells present. Three inde-
pendent fields containing at least 50 cells per field wereThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Research P G Murray et al. 3-M syndrome and IGF2 3–11 2 :227examined for each cell line and the experiment was
repeated on three occasions. A Leica CTR 5000 microscope
was used to visualise the cells incorporating EdU.Cleaved caspase-3 ELISA
Cleaved caspase-3 was measured with the PathScan
Cleaved Caspase-3 ELISA (New England Biolabs, Hitchin,
Hertfordshire, UK). Cells were seeded in 6-well plates at
1000 cells/cm2 for each cell line: 48 h after seeding, the
media were removed and cell lysate was generated as per
the manufacturer’s instructions. Absorbance at 450 nm
was measured on a u.v. spectrophotometer (Bio-Rad
Benchmark microplate reader, Bio-Rad UK).RNA extraction and transcriptome analysis
RNA was extracted from the fibroblasts using the RNAEasy
kit (Qiagen, Manchester, UK) as per the manufacturer’s
instructions and supplied to the University of Manchester
Microarray Facility (Faculty of Life Sciences, University of
Manchester, UK). RNA quality was assessed using an
Agilent 2100 Bioanalyser: 500 ng of total RNA per cell
line was reverse transcribed using a T7 Oligo dT primer.
An in vitro transcription reaction was used to generate
biotinylated cRNA, which was purified, fragmented and
hybridised to an Affymetrix HU-133 Plus 2.0 chip
(Affymetrix, Santa Clara, CA, USA).
Microarray data were analysed using Propagating
Uncertainty Microarray Analysis (PUMA – http://www.
bioinf.manchester.ac.uk/resources/puma/). This process
obtains a value for expression for each probeset on the
microarray chip and involves normalising gene expression
both within and between chips. Probesets were defined
as being up- or downregulated if there was a G1.5-fold
difference in the expression between the control and 3-M
samples with an expression level O50 (arbitrary units)
in at least one cell line.
PUMA was also used to undertake principle com-
ponent analysis (PCA) with probability of positive log-
ratio (PPLR) to examine any differences in gene expression
between control and 3-M fibroblasts. PPLR values closer
to C1 indicate those probesets that are most likely to
be upregulated and values closer to K1 indicate those
most likely to be downregulated. In addition to PCA,
quality control of the arrays was assessed with dCHIP
(http://biosun1.harvard.edu/complab/dchip/).
Gene ontology and pathway analysis were performed
with the use of the National Institute’s Health Databasehttp://www.endocrineconnections.org
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Published by Bioscientifica Ltdfor Annotation, Visualisation, Integrated Discovery (NIH
DAVID) (http://david.abcc.ncifcrf.gov/).Quantitative PCR
One microgram RNA (derived independently from the
samples used for microarray) was reverse transcribed using
the high capacity RNA to cDNA kit (Applied Biosystems).
IGF2 and H19 mRNA levels were assessed using TaqMan
assays (Hs01005963_m1 and Hs00262142_g1) with a
cyclophyllin A probe (4333763T) for control gene
expression. The other genes were assayed using SYBR
green with GAPDH as the control gene (primer sequences
available on request). Relative fold gene expression for the
target gene in the 3-M cell lines was calculated as 2KDDCT.
For each experiment, three independent RNA extractions
were assayed with three technical replicates.Methylation analysis of H19 and IGF2
One microgram peripheral leukocyte or fibroblast-
derived genomic DNA was treated with bisulphite using
the EZ-DNA Methylation kit, according to manufacturer’s
instructions (ZymoResearch, Orange, CA, USA), except that
DNA was eluted in 50 ml. Methylation-specific PCRs were
performed in duplicate within the H19 promoter and IGF2
DMR0 (as described in Poole et al. (17)) and the products
were visualised by capillary electrophoresis on an ABI 3130
Genetic Analyzer (Applied Biosystems). Peak height ratio-
metry was performed and normalised to control samples.
Pyrosequencing was performed in duplicate,
interrogating both the H19 ICR (as described in Poole
et al. (17)) and IGF2P0 DMR0 (as described in Murrell
et al. (18)). Primer sequences for all assays are provided
in Tables 1 and 2.Measurement of IGF-II in cell culture medium
Conditioned cell culture medium was obtained by
incubating serum-free media with the relevant skin
fibroblast cell line for 7 days. IGF-II levels were measured
using an Active Non-Extraction IGF-II ELISA (Beckman
Coulter, High Wycombe, Buckinghamshire, UK). IGF-II
concentrations are much lower in cell culture medium
than serum (for which the kit was designed) and this
required some amendment to the standard kit protocol.
Up to 400 ml conditioned cell culture medium was added
to 550 ml sample buffer 1 and incubated at room
temperature for 30 min: 950 ml sample buffer 2 was then
added and the tube was vortexted. Fifty microlitre of theThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 1 Primer sequences for methylation-specific PCR.
DMR Chr
Chromosomal
location
GRCh37
Methylated
allele size
Unmethylated
allele size
Methylated
primer
Unmethylated
primer
Universal
FAM-labelled
primer
H19
promotor
11p15 chr11:
2 019 455–
2 019 764
pat 295 mat 305 CGTTTGTTAGTA-
GAGTGCGTTCGC-
GAGTCG
GGTTGTTTATTGTTT-
GTTAGTA-
GAGTGTGTTTGTG
ATAACAGAAAAAAC-
CCCTTCCTACCAC-
CATCAC
IGF2P0 11p15 chr11:
2 169 485–
2 169 651
pat 155 mat 163 GTTTGACGAGGT-
TAGTGAGG-
GACGGCG
ATAGTTTTGTTTGAt-
GAGGTTAGT-
GAGGGATGGTG
CCAAAACAATTTCCC-
TAAAAATACTCATT-
CATAC
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Research P G Murray et al. 3-M syndrome and IGF2 4–11 2 :228treated samples were added to each well of the ELISA plate
and the remainder of the process was performed as per the
manufacturer’s instructions. Total protein concentration
was measured in the conditioned media using Bio-Rad
protein assay dye reagent (Bio-Rad) as per the manufac-
turer’s instructions. Protein concentration of the control
media was normalised to 1 and the IGF-II concentration
adjusted for the total protein concentration in each cell
line’s conditioned media.Results
Whole transcriptome analysis
There were 644 probesets identified as being upregulated
and 658 identified as being downregulated in all three
groups of 3-M patients compared with controls (Fig. 1).
The top 10 up- and downregulated probesets are listed in
Tables 3 and 4 respectively. Table 5 lists the top 20 up- and
downregulated probesets for each cell line (CUL7, OBSL1
or CCDC8 mutation) and indicates which of these
probesets are shared between more than one group. The
majority of probesets is shared between more than one
group and this suggests that there is a common set of genes
dysregulated in 3-M syndrome.
Among the upregulated probesets were two homeo-
box genes, HOXC6, a transcription factor expressed in theTable 2 Primer sequences for pyrosequencing.
DMR Chr
Chromosomal
location
GRCh37
Methylated
allele size
Unmethyla-
ted allele
size Prime
IGF2
DMR0
11p15 chr11:
2 169 328–
2 169 582
NA NA TGAG
TTT
H19
ICR1
11p15 chr11:
1 977 650–
1 977 877
NA NA GTAT
TAT
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Published by Bioscientifica Ltddeveloping skeleton (19), and HOXA9, a transcription
factor involved in myeloid differentiation linked with
increased cell proliferation in leukaemia (20). Other
upregulated genes included GPC6 (loss of function
mutations result in the short stature condition omodys-
plasia (21)) as well as zinc finger protein of cerebellum 1
(ZIC1) and PCP4 both of which are known to be
differentially expressed in tumours (22, 23). Three out of
the top 10 downregulated probesets represented IGF2
which encodes a 7.5 kDa secreted hormone known to be
a regulator of intra-uterine growth (24).
Q-PCR validation of a six up-and downregulated genes
was undertaken (Table 6). In all cases, the Q-PCR result
confirmed the findings on the microarray.
Gene ontology analysis of the top 500 up- and
downregulated probesets comparing all four 3-M cell
lines with controls identified terms including skeletal
system morphogenesis, cell adhesion and cell–cell
signalling as being over represented (Benjamini–Hochberg
adjusted P value !0.05). Cellular compartment terms
significantly over-represented all related to the extra-
cellular region.
Of the differentially regulated genes identified, the
gene most closely linked with impaired growth was IGF2.
Hypomethylation of the H19 differentially methylated
region leads to IGF2 silencing in the Silver–Russell
syndrome (SRS) (25). SRS shares key features with 3-Mr 1 Primer 2 (biotinylated) Sequencing primer(s)
GATGGG-
TTGTTTGGTAT
TCCTCAATCCACC-
CAAAATAATAT
AAAAGTTATTGGATA-
TATAGT or
GGGGTGGAGGGT-
GTA
AGTATATGGG-
TTTTGGAGG
CCATAAATATCC-
TATTCCCAAA-
TAACC
GTTTYGGGTTATT-
TAAGTT
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
CUL7 OBSL1
123
252
644
261 281
134
CCDC8
96
A
B CUL7 OBSL1
384
564
658
638 203
84
CCDC8
180
Figure 1
Venn diagrams of (A) up- and (B) downregulated probesets with expression
level O50 and fold change (FC) OG1.5 compared to control.
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Research P G Murray et al. 3-M syndrome and IGF2 5–11 2 :229syndrome, namely the pre- and post-natal growth restric-
tion with normal head size and triangular facies. It was
therefore decided to focus further studies on IGF2.IGF2 expression and protein concentrations in
conditioned cell culture media
Q-PCR using three independently extracted RNA samples
(each sample run in triplicate) confirmed the decrease in
IGF2 expression with relative fold expression of 0.0019G
0.0009 for CUL7 (P!0.001), 0.0155G0.0021 for OBSL1M
(P!0.001), 0.0497G0.0170 for OBSL1F (P!0.001) andhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0065
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Published by Bioscientifica Ltd0.1355G0.0146 for CCDC8 (P!0.001) compared with
controls (Fig. 2).
Although not present in the top 10 upregulated
probesets, the H19 non-coding RNA was represented by
the 23rd most upregulated probeset (FC 38, PPLR 1).
Q-PCR of H19 confirmed that it was upregulated in all
four 3-M cell lines (Fig. 2). Relative fold expression was
2.5G0.8 for CUL7 (P!0.001), 140G53 for OBSL1M
(P!0.001), 72G12 for OBSL1F (P!0.001) and 1106G435
for CCDC8 (P!0.001).
Concentrations of IGF-II were reduced in conditioned
cell culture media from all four 3-M cell lines compared
with control cell lines (Fig. 3). The mean IGF-II concen-
tration for the three control cell lines after adjustment
for total protein concentration in the media was 10.2G
2.9 ng/ml, compared with 0.1G0.2 ng/ml for the CUL7
cell line (P!0.001), 0.3G0.4 ng/ml for the OBSL1M
cell line (P!0.001), 0.4G0.5 ng/ml for the OBSL1F cell
line (P!0.001) and 1.6G1.3 ng/ml for the CCDC8 cell
line (P!0.001).
Overexpression of H19 and silencing of IGF2 in SRS
are caused by changes in methylation in the H19
differentially methylated region. Methylation-specific
PCR and pyrosequencing of the H19 ICR, H19 promotor
and IGF2 DMR0 identified no differences in methylation
between control and 3-M syndrome subjects, for both
peripheral leucocyte and fibroblast-derived DNA.Cell proliferation and apoptosis
Cell proliferation was assessed via incorporation of
EdU and by a WST-8 assay. Incorporation of EdU 48 h
after its addition to cell culture media was reduced for all
3-M fibroblast cell lines compared with control (Fig. 4A,
P!0.05), while cell proliferation as measured by colori-
metric change induced by WST-8 was reduced at 48 and
72 h after seeding for 3-M fibroblast cell lines compared
with control (Fig. 4B, P!0.05). Cleaved caspase-3,
a biomarker of apoptosis was not significantly different
between control and 3-M fibroblasts (Fig. 4C).Discussion
The aim of this study was to identify novel pathogenic
mechanisms underlying the growth failure of patients
with 3-M syndrome, which could potentially be relevant
to other patients born SGA with the failure of post-natal
growth but no defined aetiology. Previous work has
examined the role of CUL7 and OBSL1 either in mouse
studies or using gene overexpression or knockdownThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 3 Top 10 upregulated probesets comparing all 3-M cell lines (nZ4) with control (nZ3).
Gene title Gene symbol
Mean expression
level control
Mean expression
level 3-M
Fold difference
3-M/control PPLR
Zic family member 1 ZIC1 0.16 171.85 1087.41 1.00
Purkinje cell protein 4 PCP4 0.36 185.70 513.42 1.00
Homeobox C6 HOXC6 2.40 615.78 256.07 0.99
Homeobox A10 HOXA10 1.40 311.76 223.27 0.55
Homeobox A9 HOXA9 1.83 346.95 189.98 1.00
Interleukin 13 receptor,
alpha 2
IL13RA2 6.27 779.20 124.27 1.00
Collagen, type XIV, alpha 1 COL14A1 1.28 145.45 113.88 1.00
Glypican 6 GPC6 5.51 591.28 107.25 1.00
Clusterin CLU 7.84 795.86 101.45 1.00
Solute carrier member 15 SLC6A15 1.42 117.15 82.29 1.00
PPLR, probability of positive log-ratio.
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Research P G Murray et al. 3-M syndrome and IGF2 6–11 2 :230strategies in immortalised cancer cell lines. The
limitations of mouse studies are clear from the death of
the mice in the neonatal period (a feature not commonly
seen in humans with 3-M syndrome). The mouse thus
gives no opportunity to study the effects on post-natal
growth and also indicates significant differences in the
result of loss of CUL7 between species. Studies using
temporary over/under expression strategies in immorta-
lised cells yield useful data, but the extrapolation from
these findings to normal human growth is not clear. This
study therefore used patient-derived fibroblast cell lines.
It is clear that there is a common set of genes
dysregulated in 3-M syndrome. The top upregulated
gene was Zic1, a transcription factor which, in mouse, is
predominantly expressed within the nervous system with
the highest levels of expression in the cerebellum (26).
ZIC1 expression is downregulated in gastric carcinomas
(23) and increased in desmoid tumour fibroblasts (27) and
brain tumours (medulloblastomas and meningiomas)Table 4 Top 10 downregulated probesets comparing all 3-M cell
Gene title Gene symbol
Mean expre
level con
Insulin-like growth factor 2 IGF2 2118.8
Leptin LEP 64.6
Insulin-like growth factor 2 IGF2 94.1
Brain expressed, X-linked 1 BEX1 369.4
Prostaglandin D2 synthase
21 kDa (brain)
PTGDS 136.4
Collagen, type IV, alpha 1 COL4A1 199.3
Leucine-rich repeat-containing G
protein-coupled receptor 5
LGR5 270.2
Insulin-like growth factor 2 IGF2 44.9
Glutamate receptor, ionotropic,
kainate 2
GRIK2 44.5
WAP four-disulfide core domain 1 WFDC1 37.8
PPLR, probability of positive log-ratio.
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Published by Bioscientifica Ltd(28, 29). Several other genes in the top 10 upregulated
probesets are also overexpressed in tumours including
PCP4 in leiomyomas (22), HOXC6 in oesophageal (30),
breast (31) and lung carcinomas (32) and IL16RA2 in
glioblastomas (33), prostate cancer and adrenocortical
tumours (34). This indicates that their overexpression in
3-M fibroblasts could be an attempt to increase cell
proliferation. Data on siRNA-mediated knockdown and
overexpression of HOXC6 in a gastric carcinoid cell line
are consistent with this hypothesis as overexpression
leads to improved growth while loss of HOXC6 leads to
impaired cell growth (35).
Glypican 6 (GPC6), in the top 10 downregulated
probesets, is a heparan sulphate proteoglycan, which is
linked to the extracellular surface of the cell membrane.
Glypicans are expressed during development and are
thought to control availability of local growth factors (36).
Loss of function mutations in GPC6 lead to impaired
endochondral ossification and cause the short staturelines (nZ4) with control (nZ3).
ssion
trol
Mean expression
level 3-M
Fold difference
3-M/control PPLR
4 0.06 K38 253.37 0.00
9 0.10 K642.51 0.00
5 0.17 K549.78 0.00
0 1.30 K283.28 0.00
9 0.62 K219.06 0.00
7 1.09 K183.08 0.03
0 1.51 K179.24 0.01
5 0.29 K157.09 0.00
4 0.35 K126.79 0.00
4 0.37 K101.50 0.00
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 5 Top 20 up- and downregulated probesets in the 3-M group as a whole and in each cell line by mutation.
Up-regulated probesets Down-regulated probesets
3-M CUL7 OBSL1 CCDC8 3-M CUL7 OBSL1 CCDC8
ZIC1a PCP4a ZIC1a XIST IGF2a IGF2a IGF2a IGF2a
PCP4a ZIC1a PCP4a ZIC1a LEPa LGR5b LEPa CADM1
HOXC6a HOXA10a HOXC6a HOXC6a IGF2a COL4A1b EDIL3c PSG2
HOXA10a COL14A1b COL14A1b HOXA10a – SFRP2 IGF2a IGF2a
HOXA9a HOXA9a SNCAc HOXA9a BEX1a LEPa – DDX3Y
IL13RA2a IL13RA2a HOXA10a PCP4a PTGDSb DIO2 COL4A1b LGR5
COL14A1b THBS4 HOXA9a PAX6 COL4A1b APOEc BEX1a PTGDS
GPC6a – CLUb EMCN LGR5b RARRES2b PTGDSb PSG3
CLUb HOXA11b – XIST IGF2a NID2 IGF2a BEX1a
SLC6A15b HOXC6a CYP3A5 PAX6 GRIK2c TFAP2Ab HAPLN1 RPS4Y1
HOXA10a TNXB SLC6A15b GPC6a WFDC1c – IGFBP5 MAOA
HOXA11b KCNB1 IL13RA2a CLUb TFAP2Ab LXN RARRES2b GRIK2
– WIF1 GPC6a IL13RA2a RARRES2b IGF2a WFDC1c TFAP2Ab
CLUb GPC6a CLUb HOXA10a APOEc TLR4a HAPLN1 LEPa
– HOXA10a SPON1c XIST WNT5Ac APOEc SYNPO2c IGF2a
ABCA6b ST8SIA1 SCARA3c WISP1 EDIL3c ITIH5c WNT5Ac TRPC6
SCARA3c ACE HOXA10a THBD SIM2 PMEPA1 IGFBP7 FAM19A5
HOXA9a SLC6A15b ABCA6b THBD – PSG7 TPD52L1 ITIH5c
SPON1c COL14A1b SPON1c H19 SYNPO2c DIO2 MRVI1 ITIH5c
TBX5 ABCA6b SNX10 SNCAc PPP1R14A BEX1a STXBP6 USP9Y
aProbesets present in all groups; bprobesets present in the 3-M group and two mutation groups; cprobesets present in the 3-M group and one
mutation group. –, probeset is designed to a gene which was not named at the time of the study.
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Research P G Murray et al. 3-M syndrome and IGF2 7–11 2 :231condition omodysplasia (21). Loss of function mutations
in glypican 3 (GPC3) causes the overgrowth disorder
Simpson–Golabi–Behmel syndrome (SGBS). GPC3 inter-
acts with IGF-II and it was initially hypothesised that
GPC3 binds to and sequesters IGF-II; thus the overgrowth
in SGBS is caused by increased availability of IGF-II (37).
More recent data on mouse indicate that the overgrowth
of Gpc3 null mice is independent of IGF-II (38), while data
on the role of GPC3 in the growth of cancer cell lines
are inconsistent with some studies suggesting that GPC3
suppressed growth in an IGF-dependant manner (39)
while others identified GPC3 as a growth-promoting
protein (40, 41). Of note, of the two probesets in our
microarray designed to detect the expression of GPC3,Table 6 Additional validation of gene expression data. Expressi
microarray were assessed with Q-PCR. Relative fold expression for ea
cell lines. Expression was normalised to GAPDH and mean control c
Gene
CUL7 OBSL1 F
Relative
expression P
Relative
expression P
BEX1 0.06G0.01 !0.001 0.15G0.20 !0.00
LEP 0.07G0.04 !0.001 0.06G0.03 !0.00
ZIC1 946G462 !0.001 496G186 0.00
HOXC6 31G24 0.006 88G55 0.00
HOXA9 690G586 0.008 501G466 0.01
GPC6 35G6 !0.001 44G10 !0.00
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Published by Bioscientifica Ltdone did not detect expression of GPC3 (defined in this
study as an expression level O50) in any cell line while
the other probeset identified a modest downregulation
(FC K1.76 PPLR 0.44).
Three of the top 10 downregulated probesets
represented IGF2 with the smallest fold change being
K157. The second most downregulated probeset rep-
resented leptin, a 16 kDa adipocyte-derived hormone
which plays a central role in the regulation of body
weight, both by inhibiting food intake and increasing
energy expenditure (42, 43). Downregulation of leptin
in 3-M syndrome may represent a response to the
patients slim body habitus or be a signal to drive energy
intake in order to promote growth. BEX1, PTGDS,on of genes identified as being up- or downregulated in the
ch of the seven genes analysed is given for each of the four 3-M
ell line expression.
OBSL1 M CCDC8
Relative
expression P
Relative
expression P
1 0.03G0.02 !0.001 0.20G0.24 !0.001
1 0.01G0.00 !0.001 0.04G0.01 !0.001
4 1200G891 !0.001 759G498 0.002
1 51G38 0.005 100G87 0.009
2 349G296 0.008 399G342 0.008
1 7G2 !0.001 5G1 !0.001
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Relative fold expression of (A) IGF2 and (B) H19 measured using
quantitative PCR in all 3-M cell lines. Expression of IGF2 is reduced while
H19 is increased. *P!0.05.
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IGF-II concentrations in conditioned cell culture media are significantly
reduced for all 3-M syndrome fibroblast cell lines. *P!0.05 compared to
control. IGF-II concentrations are adjusted for total protein concentration
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Research P G Murray et al. 3-M syndrome and IGF2 8–11 2 :232GRIK2 and WFDC1, also in the top 10 downregulated
probesets, have all been identified as downregulated in
tumours (44, 45) or as inhibitors of cell proliferation in
immortalised cell lines (46, 47, 48). Thus in common
with several of the genes identified as being upregulated
these changes are likely to represent a response to
increase cell proliferation.
While many of the identified changes in gene
expression, such as the overexpression of GPC6, are likely
to be a compensatory response to the growth impairment,
we hypothesised that there would be a smaller number
of genes with altered expression which are key to the
pathogenic process underlying 3-M syndrome. The most
obvious of such candidate was IGF2, which was rep-
resented by three of the top 10 downregulated probesets.
The encoded protein IGF-II is a 7.5 kDa secreted hormone
that acts to increase cell proliferation via stimulation
of the IGF1R. It is widely expressed during the develop-
ment and is a major regulator of intra-uterine growth.http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0065
 2013 The authors
Published by Bioscientifica LtdIGF2 expression is regulated by methylation of the H19
region (H19 DMR); hypomethylation of the H19 DMR
with subsequent IGF2 gene silencing leads to the short
stature condition SRS (25). SRS shares several key features
with 3-M syndrome: intra-uterine growth retardation,
post-natal growth impairment, relatively normal head
size, normal intelligence and a triangular shaped face.
Other downregulated genes identified which could poten-
tially be implicated in the pathogenesis of 3-M syndrome
included LGR5 (a member of the G-protein-coupled
receptor superfamily) and COL4A1 (the main component
of type IV collagen which forms basement membrane);
silencing of expression of these genes is associated with
decreased cell proliferation (49) while in tumours (50, 51),
they have been found to be upregulated. Of the top 10
upregulated probesets, the only gene identified as poten-
tially being involved in the pathogenesis of 3-M syndrome
was COL14A1, a large glycoprotein of the extracellular
matrix which has an anti-proliferative effect on fibroblasts
(52) and knockdown in renal cancer cells, which results
in increased growth (53).
Given the findings of reduced IGF-II production from
3-M syndrome fibroblasts, it is likely that local production
of IGF-II is reduced with loss of its autocrine/paracrine
effects. Loss of local IGF-II in the growth plates and other
tissues leads to growth impairment both pre- and post-
natally. The reduced cell proliferation with no change
found in a biomarker of apoptosis would be consistent
with a reduction in the presence of a growth factor. While
there is significant phenotypic overlap between 3-MThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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These are likely to be due to additional functions of the
proteins affected in 3-M syndrome.
The mechanisms through which IGF2 expression is
reduced in 3-M syndrome remain unclear. It does not
appear to be via the same mechanism as is found in SRS,
i.e. hypomethylation at H19 DMR. It is possible that
there may be an epigenetic change which has not been
recognised but this appears unlikely. There may be
another mechanism, such as alteration in CCCTC-binding
factor concentrations or activity that could lead to the
same gene expression pattern.
Height at presentation in 3-M syndrome is lowest
in patients with CUL7 mutations and highest in those
with CCDC8 mutations (13). Of interest, the pattern of
IGF2 expression and IGF-II production mirrored the
growth phenotype of the patients with the lowest IGF-II
production in the CUL7 cell line and the highest IGF-II
production in the CCDC8 cell line.
In conclusion, this study demonstrates that there is
reduced expression of IGF2 in 3-M syndrome linking the
pathogenesis to that of SRS. The mechanisms underlying
the silencing of IGF2 in 3-M syndrome are unclear, but do
not appear to involve hypomethylation at the H19 DMR.Declaration of interest
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